Mayinglong Pharmaceutical Group , Ltd. EBIT

Mayinglong Pharmaceutical Group , Ltd. (600993.SS) currently reports a EBIT of $720M as of June 2026. That compares with $700M in the prior-year period — up 2.5% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Mayinglong Pharmaceutical Group , Ltd.'s EBIT history and peer comparisons.

Mayinglong Pharmaceutical Group , Ltd.'s EBIT increased from $700M to $720M — a 2.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mayinglong Pharmaceutical Group , Ltd.'s EBIT of $720M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Mayinglong Pharmaceutical Group , Ltd. reported $720M in EBIT as of June 2026. That compares with $700M in the prior-year period — up 2.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $720M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Mayinglong Pharmaceutical Group , Ltd., and consider following 600993.SS for alerts when major investors trade the stock.